The Neupro patch patent held by UCB was found to be invalid by the United States Court of Appeals for the Federal Circuit. The U.S. Food and Drug Administration’s licencing of a generic Neupro might have been postponed if the court ruled in favour of UCB until it ran out in December 2030, the court stated.
On Wednesday, the biopharmaceutical company UCB was unsuccessful in its appeal to a U.S. court to reinstate the patent on a medication it manufactures for Parkinson’s disease, removing a barrier to the sale of generic versions of the medication by Actavis Laboratories UT Inc. of Teva and Mylan Technologies Inc. of Viatris.
The Neupro patch patent held by UCB was found to be invalid by the United States Court of Appeals for the Federal Circuit. The U.S. Food and Drug Administration’s licencing of a generic Neupro might have been postponed if the court ruled in favour of UCB until it ran out in December 2030, the court stated.

Actavis’ intended generic was prohibited by a prior court judgement based on a different patent until 2021.